TransMedics Group, Inc. TMDX

TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in two upcoming investor conferences. TransMedics management is scheduled to participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on Monday, September 14, 2026, at 3:20 p.m. EST and at the Baird 2026 Global

TransMedics Group stock has delivered a 170.9% gain over the past five years, yet the broader valuation checks currently lean toward the shares being undervalued rather than fully priced in. With recent returns mixed over shorter periods, the market seems less certain than the long term chart suggests about what the current price of US$80.75 really reflects. The 170.9% return over five years signals that long term holders in TransMedics Group have already seen substantial value creation,...

TransMedics Group Inc (TMDX) posts 21% revenue growth to $190 million, raises full-year guidance, and advances key clinical programs despite margin pressure from strategic investments.

While the top- and bottom-line numbers for TransMedics (TMDX) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended June 30, 2026.

TransMedics Group, Inc. previously announced it would report its Q2 2026 results after the market close on August 4, 2026, alongside an earnings call, while also granting stock options and restricted stock units to new employees under Nasdaq Listing Rule 5635(c)(4). UBS’s recent initiation of analyst coverage, combined with new equity awards aimed at retaining and attracting talent, highlights growing institutional attention to TransMedics’ transplant-focused technology platform and...